SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-67549"
 

Search: id:"swepub:oai:DiVA.org:uu-67549" > Can mutations in EL...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Jacobson, AnnicaUppsala universitet,Institutionen för medicinska vetenskaper,Clinical pharmacogenetics and Osteoporosis (author)

Can mutations in ELA2, neutrophil elastase expression or differential cell toxicity explain sulphasalazine-induced agranulocytosis?

  • Article/chapterEnglish2004

Publisher, publication year, extent ...

  • 2004-12-02
  • Springer Science and Business Media LLC,2004
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-67549
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-67549URI
  • https://doi.org/10.1186/1471-2326-4-5DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Drug-induced agranulocytosis, a severe side effect marked by a deficit or absolute lack of granulocytic white blood cells, is a rare side-effect of the anti-inflammatory drug sulphasalazine. Mutations in the human neutrophil elastase gene (ELA2), causing increased intracellular concentration of this serine protease, inhibits neutrophil differentiation in severe congenital neutropenia (SCN). Since the clinical symptoms of agranulocytosis and SCN are similar, we hypothesized that it may origin from a common genetic variation in ELA2 or that sulphasalazine may affect human neutrophil elastase activity and protein expression. METHODS: We screened for genetic differences in ELA2 in DNA from 36 patients who had suffered from sulphasalazine-induced agranulocytosis, and compared them with 72 patients treated with sulphasalazine without blood reactions. We also performed in vitro studies of the blood cell lines HL60 and U937 after sulphasalazine exposure with respect to cell survival index, neutrophil elastase protein expression and activity. RESULTS: None of the mutations in ELA2, which previously have been reported to be associated with SCN, was found in this material. Protein expression of human neutrophil elastase in lymphoma U937 cells was not affected by treatment with concentrations equivalent to therapeutic doses. Cell survival of lymphoma U937 and promyelocytic leukemia HL-60 cells was not affected in this concentration range, but exhibited a decreased proliferative capacity with higher sulphasalazine concentrations. Interestingly the promyelocytic cells were more sensitive to sulphasalazine than the lymphoma cell line. CONCLUSION: Neutrophil elastase expression and ELA2 mutations do, however, not seem to be involved in the etilogy of sulphasalazine-induced agranulocytosis. Why sulphasalazine is more toxic to promyelocytes than to lymphocytes remains to be explained.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Melhus, HåkanUppsala universitet,Institutionen för medicinska vetenskaper,Clinical pharmacogenetics and Osteoporosis(Swepub:uu)hakamelh (author)
  • Wadelius, MiaUppsala universitet,Klinisk farmakogenomik och osteoporos(Swepub:uu)miawadel (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:BMC Blood Disorders: Springer Science and Business Media LLC4:1, s. 5-1471-2326
  • In:BMC Hematology: Springer Science and Business Media LLC4:1, s. 5-2052-1839

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Jacobson, Annica
Melhus, Håkan
Wadelius, Mia
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Medical Genetics
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Pharmacology and ...
Articles in the publication
BMC Blood Disord ...
BMC Hematology
By the university
Uppsala University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view